Neuland Laboratories reported a strong Q1 FY27, with revenue rising 119.2% YoY to ₹641.58 crore and PAT surging 962.4% YoY to ₹147.67 crore. The company also announced a long-term CDMO partnership with Gland Pharma and approved a ₹39.8 crore capacity expansion. Ace investor Mukul Agrawal continued to hold a 3.12% stake in the June 2026 quarter.